Cargando…

Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study

BACKGROUND: Immunization with meningococcal ACWY conjugate vaccine induces protective antibodies against invasive meningococcal disease (IMD) caused by serogroups A, C, W and Y. We studied MenACWY-TT vaccine immunogenicity in adolescents with a heterogenous group of primary and secondary immune defi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohm, Milou, van Straalen, Joeri W, de Joode-Smink, Gerrie, van Montfrans, Joris, Bartels, Marije, van Wildenbeest, Joanne G, Lindemans, Caroline A, Wennink, Roos AW, de Boer, Joke H, Sanders, Elisabeth AM, Verduyn-Lunel, Frans M, Berbers, Guy AM, Wulffraat, Nico M, Jansen, Marc H.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360259/ https://www.ncbi.nlm.nih.gov/pubmed/37475057 http://dx.doi.org/10.1186/s12969-023-00846-3

Ejemplares similares

Different Long-Term Duration of Seroprotection against Neisseria meningitidis in Adolescents and Middle-Aged Adults after a Single Meningococcal ACWY Conjugate Vaccination in The Netherlands
por: Ohm, Milou, et al.
Publicado: (2020)

Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
por: Ohm, Milou, et al.
Publicado: (2021)

Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2016)

Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015–2016
por: Campbell, Helen, et al.
Publicado: (2017)

Determinants of Meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations
por: Cheng, Wendy Y., et al.
Publicado: (2019)

2459. Meningococcal ACWY (MenACWY) Vaccination of Adolescents in the United States: How Compliant Are We With the Advisory Committee on Immunization Practices (ACIP) Recommendations?
por: Cheng, Wendy, et al.
Publicado: (2018)

Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine
por: Watle, Sara Viksmoen, et al.
Publicado: (2021)

Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018
por: Knol, Mirjam J, et al.
Publicado: (2018)

Sex-Related Differences in the Immune Response to Meningococcal Vaccinations During Adolescence
por: Ohm, Milou, et al.
Publicado: (2022)

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10–25 Years of Age
por: Halperin, Scott A., et al.
Publicado: (2014)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK
por: Hadley, Liza, et al.
Publicado: (2023)

Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile
por: Graña, María Gabriela, et al.
Publicado: (2021)

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2017)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK – ERRATUM
por: Hadley, Liza, et al.
Publicado: (2023)

Protection against invasive meningococcal disease and vaccination policy in the Netherlands
por: Ohm, M, et al.
Publicado: (2022)

1478. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
por: Quiambao, Beatriz, et al.
Publicado: (2019)

2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
por: Quiambao, Beatriz, et al.
Publicado: (2019)

Does social deprivation correlate with meningococcal MenACWY, Hib/MenC and 4CMenB/Meningococcal Group B vaccine uptake in Northern Ireland?
por: Brennan, Orlaith C., et al.
Publicado: (2022)

A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines
por: Findlow, Jamie, et al.
Publicado: (2019)

Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review
por: Presa, Jessica, et al.
Publicado: (2019)

3. A Review of the Clinical Development of MenACWY-TT, a Quadrivalent Meningococcal Vaccine Conjugated to Tetanus Toxoid, in Adolescents
por: Peyrani, Paula, et al.
Publicado: (2020)

Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines
por: Serra, Lidia, et al.
Publicado: (2021)

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2023)

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine
por: Vesikari, Timo, et al.
Publicado: (2015)

A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine
por: Ruiz Garcia, Yara, et al.
Publicado: (2021)

Correction to: A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine
por: Ruiz Garcia, Yara, et al.
Publicado: (2021)

Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK: Does the Adolescent MenACWY Programme Provide Sufficient Protection?
por: Schley, Katharina, et al.
Publicado: (2023)

The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis
por: Hamad Saied, Mohamad, et al.
Publicado: (2023)

Psychosocial and organizational barriers and facilitators of meningococcal vaccination (MenACWY) acceptance among adolescents and parents during the Covid-19 pandemic: a cross-sectional survey
por: Widdershoven, Veja, et al.
Publicado: (2022)

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
por: Marshall, Gary S., et al.
Publicado: (2022)

Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM
por: Kim, Han Wool, et al.
Publicado: (2016)

Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine
por: van Ravenhorst, Mariëtte B., et al.
Publicado: (2018)

Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study
por: Kemmeren, J. M., et al.
Publicado: (2021)

14. Postmarketing Safety Experience With MenACWY-TT
por: Serra, Lidia, et al.
Publicado: (2021)

Real-world impact and effectiveness of MenACWY-TT
por: Villena, Rodolfo, et al.
Publicado: (2023)

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children
por: Knuf, Markus, et al.
Publicado: (2012)

Use of MenACWY-CRM Vaccine in Children Aged 2 Through 23 Months at Increased Risk for Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2013
por: MacNeil, Jessica R., et al.
Publicado: (2014)

1085 Persistence of Meningococcal Bactericidal Antibodies and Booster Response at 60-Months of Age in Children Who Received Infant Or Toddler Doses of MenACWY-CRM Conjugate Vaccine
por: Klein, Nicola P., et al.
Publicado: (2014)

Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra(®)) in the Republic of Korea, 2014–2019
por: Kim, Hee Soo, et al.
Publicado: (2021)

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands
por: Kaaijk, Patricia, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bqqo3vhbvg7njoeuq2eknsf2ff